Nevertheless, the heterozygous loss of the B4galnt1 gene leads to a partial decrease in GM1 similar to that observed in PD patients [187,188,204,205,206,207] and can be used for studies of replacement therapy using GM1. This evidence concerns the gene B4GALNT1 and Parkinson disease.